Poland· PL-100239590
Velmetia
A metformin and sitagliptin product containing sitagliptinum + metformini hydrochloridum, registered in Poland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Metformin and sitagliptin is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BD07 (metformin and sitagliptin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Metformin and sitagliptin · ATC A10BD07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Sitagliptinum + Metformini hydrochloridum
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Poland (PL)
- ATC code
- A10BD07
- ATC class
- Metformin and sitagliptin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 7
- gtin05909990837779
- gtin05909990837786
- gtin05909990837809
- gtin05909990837830
- gtin05909990837847
- gtin05909990837854
- gtin05909990837793
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
3 interactions on record for metformin and sitagliptin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and sitagliptin · interactions on record
3 records
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and sitagliptin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaASIGEFORTTAD Pharma GmbH, Cuxhaven
- SpainDISIMET 50 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGLaboratorios Alter S.A.
- SwitzerlandJanumet
- NetherlandsEfficib 50 mg/1000 mg, filmomhulde tablettenMerck Sharp & Dohme B.V.
- United StatesJANUMETA-S Medication Solutions
- SwedenEfficib 50 mg/1000 mg Filmdragerad tablettMerck Sharp & Dohme BV
- FinlandBrandasitGenepharm S.A.
- ItalyADIABINPHARMEXTRACTA S.P.A.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Jamesi, Jansitin Duo
- Belgium · Sitagliptin/Metformin Grindeks, Sitagliptin/Metformin Sandoz
- Bulgaria · Jansitin Duo, Metlinka 50 Mg/1000 Mg
- Cyprus · Diabremet, Jivolar
- Czechia · Ansifora Duo, Asigefort
- Germany · Metformax Combi, Metsunix
- Denmark · Glerova, Sitagliptin/Metformin "sandoz"
- Estonia · Asigefort, Diabremet
- Spain · Disimet, Estequen
- Finland · Brandasit, Sitagliptin/Metformin Glenmark
- France · Sitagliptine/Chlorhydrate De Metformine Micro Labs, Sitagliptine/Chlorhydrate De Metformine Olpha
- United Kingdom (Northern Ireland) · Sitagliptin / Metformin Hydrochloride Macleods, Sitagliptin / Metformin Hydrochloride Macleods Pharma Uk
- Greece · Brandasit, Co-Fineria
- Croatia · Condias Combi, Eprocliv
- Hungary · Ansifora Duo, Asigefort
- Ireland · Sitagliptin And Metformin Hydrochloride Ascend, Sitagliptin/Metformin Clonmel
- Iceland · Aps, Efficib
- Italy · Adiabin, Diesmit
- Liechtenstein · Efficib, Janumet
- Lithuania · Asigefort, Eprocliv
- Latvia · Asigefort, Eprocliv
- Malta · Combodiab Galenicum Health, Diabremet
- Netherlands · Eprocliv, Fordiab
- Norway · Efficib, Janumet
- Portugal · Jivolar, Metformina + Sitagliptina Alter
- Romania · Eprocliv, Jamesi
- Sweden · Jivolar, Mifomet
- Slovenia · Eprocliv, Jivolar
- Slovakia · Ansifora Duo, Asigefort
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e29f463d-7b8c-4479-97df-7ed2435de863 GET /v1/drugs/e29f463d-7b8c-4479-97df-7ed2435de863?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg + 850 mg",
"packaging": "05909990837779 ¦ Rp ¦ EU/1/08/456/001 ¦ 63762\n14 tabl.\n05909990837786 ¦ Rp ¦ EU/1/08/456/002 ¦ 63763\n28 tabl.\n05909990837809 ¦ Rp ¦ EU/1/08/456/003 ¦ 63764\n56 tabl.\n05909990837830 ¦ Rp ¦ EU/1/08/456/004 ¦ 63765\n112 tabl.\n05909990837847 ¦ Rp ¦ EU/1/08/456/005 ¦ 63766\n168 tabl.\n05909990837854 ¦ Rp ¦ EU/1/08/456/006 ¦ 63767\n196 tabl.\n05909990837793 ¦ Rp ¦ EU/1/08/456/007 ¦ 63768\n50 tabl. (50 x 1)\nRp ¦ EU/1/08/456/006 ¦ 90513\n196 tabl. (2 x 98)\nRp ¦ EU/1/08/456/017 ¦ 90514\n168 tabl. (2 x 84)\nRp ¦ EU/1/08/456/019 ¦ 122291\n60 tabl.\nRp ¦ EU/1/08/456/020 ¦ 122292\n180 tabl.",
"substance": "Sitagliptinum 50 mg + Metformini hydrochloridum 850 mg",
"common_name": "Sitagliptinum + Metformini hydrochloridum",
"pl_product_id": "100239590",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about metformin and sitagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.